Schedule of Segment Financial Information (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Segment Reporting [Abstract] | ||||||
| Clinical | $ (20,676) | $ 1,568,812 | $ 705,645 | $ 2,439,727 | ||
| Nonclinical | 166,478 | 91,631 | 311,179 | 212,034 | ||
| Personnel related | 472,033 | 348,659 | 882,152 | 958,082 | ||
| Total research and development | 617,835 | 2,009,102 | 1,898,976 | 3,609,843 | ||
| General and administrative | 1,154,896 | 874,640 | 2,213,559 | 2,477,459 | ||
| Interest income | 71,638 | 54,636 | 107,855 | 123,934 | ||
| Net loss | $ (1,701,093) | $ (2,303,587) | $ (2,829,106) | $ (3,134,262) | $ (4,004,680) | $ (5,963,368) |
| X | ||||||||||
- Definition Research and development clinical expense. No definition available.
|
| X | ||||||||||
- Definition Research and development nonclinical expense. No definition available.
|
| X | ||||||||||
- Definition Research and development personnel related expense. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|